MNMichelle J. Naughton

Michelle J. Naughton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michelle J. Naughton has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Three-year trajectories of insomnia symptoms among young breast cancer survivors

    by Chloe M. Hery, Kayla Williams, Sarah A. Janse, Juan Peng, Faiza Kalam, Kimberly Van Zee, Elizabeth Z. Naftalis, Electra D. Paskett, Michelle J. Naughton

    Background: Sleep disruptions are common in cancer survivors and can negatively impact quality of life. Young breast cancer survivors face unique challenges and may have distinct sleep patterns. We examined trajectories of insomnia symptoms over 3 years among young survivors. Methods: 836 women, ≤45 years old with stage I-III breast cancer, were recruited to the Menstrual Cycle Maintenance and Quality of Life After Breast Cancer Study within 8 months of diagnosis. Insomnia symptoms were assessed at 6-month intervals from baseline through 3 years post-recruitment, using the Women’s Health Initiative Insomnia Rating Scale (WHIIRS). Group-based trajectory modeling was used to identify distinct trajectories of insomnia symptoms. The final model was chosen by comparing the average posterior probability of assignment (PPA) and examining the distinctiveness and interpretability of the trajectories. Key demographic, quality of life and clinical variables were assessed in multinomial logistic regression models as potential factors associated with group membership. Results: The mean age of participants was 38 years (range: 20–45 years) at enrollment. Three distinct insomnia trajectories were identified: low probability of insomnia (n=277, 33.1%), moderate probability (n=354, 42.4%), and high probability (n=205, 24.5%). Average PPA was between 75%-82% for each group. Insomnia symptoms were highest at baseline but improved for the low probability and moderate probability groups. In adjusted models, older age (p=0.02), lower education (p=0.03), having received chemotherapy (p=0.03), night sweats (p=0.02), lower SF-12 physical component scores (poorer physical functioning, p<0.0001), and lower SF-12 mental health component scores (p<0.0001) were associated with participants in the moderate and high probability insomnia groups compared to those in the low probability group. Conclusion: Insomnia symptoms are problematic for many young breast cancer survivors. Future studies are needed to determine whether early identification and intervention can modify these insomnia symptom trajectories and improve broader survivorship outcomes.

  • Open Access

    Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial

    by Joannie M. Ivory, Heather J. Gunn, Stephanie B. Wheeler, Sarah Drier, Electra Paskett, Michelle Naughton, Shaylene McCue, Rachel Wills, Kayla Williams, Selina Chow, et al.

    PURPOSE: Lack of race- and age-diversity in clinical trials adversely affects generalizability of trial results and equity of trial access. Research on barriers to representative accrual has focused on patient-level factors. We aimed to define site-level factors affecting the diversity of accrual to a multicenter clinical trial. METHODS: Alliance 191901 (GETSET) is a national randomized controlled trial testing interventions to promote breast cancer endocrine therapy adherence, which oversamples Black women and those under age 50 years at 30% thresholds. A secondary study objective is to examine site-level factors associated with accrual of Black and younger participants. At 50% accrual to the parent study, we performed prespecified analyses of association between site characteristics (region, neighborhood racial composition, Alliance membership type, number of recent accruals to cooperative research group trials) and the proportion of Black patients and younger patients accrued. We also examined trajectories of accrual over time for race- and age-specified subgroups. RESULTS: The analysis included 124 sites. Among 590 participants, 9.7% were Black, and 22.4% were age v 7.3% for West, P < .001). Neighborhood racial composition was positively associated with recruitment of Black participants (16.2% at sites from highest Black composition v 1.4% in lowest, P < .01). Recruitment trajectories of Black participants were slower than target rates, whereas those among non-Black participants were faster. CONCLUSION: Neighborhood composition and geographic region were predictors of proportions of Black participants accrued to A191901 sites, but site type and historical accrual volume were not. When trials must limit site selection, identifying sites based on neighborhood composition and geography may be an appropriate tool for increasing trial diversity.


  • Open Access

    Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

    by M.J. Naughton, D.M. Zahrieh, M. Gnant, N. Zdenkowski, J. Lemieux, J.J. Mao, V. Bjelic-Radisic, E. Shinn, M. Balic, C. Thomssen, et al.


  • Open Access

    Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol

    by Joannie Ivory, Stephanie B. Wheeler, Sarah Drier, Heather Gunn, David Zahrieh, Electra Paskett, Michelle Naughton, Rachel Wills, Kayla Swetel, Selina Chow, et al.

    Background: Hormone receptor-positive (HR +) breast cancer is the most common type of breast cancer in the USA but has excellent long-term outcomes in recent decades, in part due to effective oral endocrine therapy (ET). ET medications are typically prescribed for 5 to 10 years, depending on the risk of recurrence, and must be taken daily. One limiting factor to ET efficacy is nonadherence, with high-risk groups for nonadherence including younger women and Black women. Methods: The Alliance for Clinical Trials in Oncology (Alliance) trial A191901 is an ongoing, four-arm (text message reminder (TMR), motivational interviewing (MI), TMR plus MI, or enhanced usual care) randomized clinical trial that tests the efficacy and effect of two interventions (TMR and/or MI) on improved ET adherence, patient-reported outcomes (PROs), and resource use requirements among HR + breast cancer survivors. Participants are randomized in a 1:1:1:1 ratio to the four arms. With an assumed loss to follow-up of approximately 11%, we plan to recruit 1180 participants. Randomization is stratified based on age and race to ensure balance between the arms, and we oversample younger and Black women, with each group representing 30% of the study population. Participants randomized to an intervention will actively participate in the intervention for 9 months, and all participants will be followed for adherence data and PRO endpoints, through the use of the Pillsy cap medication event monitoring system and Alliance ePRO survey app (i.e., Patient Cloud). The primary analysis will compare Pillsy-measured ET adherence among study arms at 12 months. Discussion: This multisite study will not only define strategies to improve adherence to breast cancer oral therapies, but it will also potentially support strategies in large cooperative research groups that can increase delivery and tolerability of ET, involve diverse patient populations in clinical research, and engage patients effectively in interventional studies, using remote and cost-effective delivery methods. Trial registration: Clinicaltrials.gov NCT04379570. Registered on 7 May 2020.


  • Open Access

    Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]

    by Mirela Anghelina, Michelle J. Naughton, Qiuhong Zhao, Amy S. Ruppert, Jasmine Neal, Kerry A. Rogers, James S. Blachly, Gerard Lozanski, Seema A. Bhat, Eric Kraut, et al.

  • Correlates of physical activity among older breast cancer survivors: Findings from the Women's Health Initiative LILAC study

    by Jessica L. Krok-Schoen, Michael L. Pennell, Nazmus Saquib, Michelle Naughton, Xiaochen Zhang, Aladdin H. Shadyab, Candyce H. Kroenke, Jennifer W. Bea, Lindsay L. Peterson, Tracy Crane, et al.


  • Health‐related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients

    by Michelle J. Naughton, Heshan Liu, Drew K. Seisler, Jennifer Le‐Rademacher, Jane M. Armer, Jill M. Oliveri, Jeffrey A. Sloan, Karen Hock, Michael Schwartz, Gary Unzeitig, et al.

    Background: Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health‐related quality of life (HRQOL) in a group‐randomized trial at 38 cooperative group sites within the United States.Methods: Patients were recruited before breast surgery. Sites were randomly assigned to education‐only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a ≥10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy–Breast plus 4 lymphedema items (FACT‐B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status.Results: A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema (P = .37) or HRQOL (FACT‐B+4 total score; P = .8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance (P = .0825). However, African American patients reported greater lymphedema symptoms (P = .0002) and better emotional functioning (P = .0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age (P ≤ .0001), Eastern Cooperative Oncology Group performance status >0 (P = .0002), ≥1 positive lymph nodes (P = .0009), having no education beyond high school (P < .0001), having undergone chemotherapy (P = .0242), and having had only axillary node dissection or sentinel node biopsy versus both (P = .0007).Conclusion: The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities.


  • Open Access

    Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment

    by Michelle J. Naughton, Ritu Salani, Juan Peng, Maryam Lustberg, Cecilia DeGraffinreid, Jennifer Moon, Hibaq Loyan, Chloe M. Beverly Hery, Electra D. Paskett

    Purpose: To evaluate the feasibility of implementing systematic patient symptom monitoring during treatment using a smartphone. Methods: Endometrial [n = 50], ovarian [n = 70] and breast [n = 193] cancer patients participated in text-based symptom reporting for up to 12 months. In order to promote equity, patients without a smartphone were provided with a device, with the phone charges paid by program funds. Each month, patients completed the Patient Health Questionnaire (PHQ-9), and 4 single items assessing fatigue, sleep quality, pain, and global quality of life during the past 7 days rated on a 0 (low) –10 (high) scale. Patients’ responses were captured using REDCap, with oncologists receiving monthly feedback. Lay navigators provided assistance to patients with non-medical needs. Results: Patients utilizing this voluntary program had an overall mean age of 60.5 (range 26–87), and 85% were non-Hispanic white. iPhones were provided to 42 patients, and navigation services were used by 69 patients. Average adherence with monthly surveys ranged between 75–77%, with breast patients having lower adherence after 5 months. The most commonly reported symptoms across cancer types were moderate levels (scores of 4–7) of fatigue and sleep disturbance. At 6 months, 71–77% of all patients believed the surveys were useful to them and their health care team. Conclusions: We established the feasibility of initiating and managing patients in a monthly text-based symptom-monitoring program. The provision of smartphones and patient navigation were unique and vital components of this program.


  • Open Access

    Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18 months of diagnosis

    by Michelle J. Naughton, Chloe M. Beverly Hery, Sarah A. Janse, Elizabeth Z. Naftalis, Electra D. Paskett, Kimberly J. Van Zee

    Background: The prevalence and correlates of job and insurance problems were examined among a cohort of young U.S. breast cancer survivors during the first 18-months following diagnosis. Methods: Participants were 708 women diagnosed at ≤45 years with stage I-III breast cancer. 90% were non-Hispanic white, 76% were married/partnered and 67% had ≥4-year college degree. Univariable and multivariable logistic regression examined the associations between demographic, lifestyle and clinical factors with job and insurance problems. Results: 18-months after diagnosis, 56% of participants worked full-time, 16% part-time, 18% were homemakers and/or students, 4.5% were unemployed, and 2.4% were disabled. The majority (86%) had private insurance. Job-related problems were reported by 40% of women, and included believing they could not change jobs for fear of losing health insurance (35.0%), being fired (2.3%), and being demoted, denied promotion or denied wage increases (7.8%). Greater job-related problems were associated with being overweight vs. under/normal weight (p = 0.006), income <$50,000/per year (p = 0.01), and working full-time vs. part-time (p = 0.003). Insurance problems were reported by 27% of women, and included being denied health insurance (2.6%), health insurance increases (4.3%), being denied health benefit payments (14.8%) or denied life insurance (11.4%). Insurance problems were associated with being under/normal weight vs. obese (p = 0.01), not being on hormone therapy (p < 0.001), and a tumor size > 5 cm vs. < 2 cm (p = 0.01). Conclusions: Young survivors experienced significant job- and insurance-related issues following diagnosis. To the extent possible, work and insurance concerns should be addressed prior to treatment to inform work expectations and avoid unnecessary insurance difficulties.


  • Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105

    by Michelle J. Naughton, L. Douglas Case, Ann Peiffer, Michael Chan, Volker Stieber, Dennis Moore, Steven Falchuk, James Piephoff, William Edenfield, Jeffrey Giguere, et al.

    The health-related quality of life (HRQL) and fatigue of brain cancer survivors treated with donepezil or placebo for cognitive symptoms after radiation therapy were examined. One hundred ninety-eight patients who completed >30 Gy fractionated whole or partial brain irradiation at least 6 months prior to enrollment were randomized to either placebo or donepezil (5 mg for 6 weeks followed by 10 mg for 18 weeks) in a phase 3 trial. A neurocognitive battery, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, was administered at baseline, 12 weeks, and 24 weeks. At 12 weeks, donepezil resulted in improvements in only emotional functioning (P = .04), with no significant effects at week 24. Associations by level of baseline cognitive symptoms (above or below the median score of the baseline FACT-Br “additional concerns/brain” subscale), indicated that participants with more baseline symptoms who received donepezil versus placebo, showed improvements in social (P = .02) and emotional well-being (P = .038), other concerns/brain (P = .003) and the FACT-Br total score (P = .004) at 12 weeks, but not 24 weeks. However, participants with fewer baseline symptoms randomized to donepezil versus placebo reported lower functional well-being at both 12 (P = .015) and 24 weeks (P = .009), and greater fatigue (P = .02) at 24 weeks. The positive impact of donepezil on HRQL was greater in survivors reporting more baseline cognitive symptoms. Donepezil had significantly worse effects on fatigue and functional well-being among participants with fewer baseline symptoms. Future interventions with donepezil should target participants with more baseline cognitive complaints to achieve greater therapeutic impact and lessen potential side effects of treatment.